Analysts at Barclays PLC initiated coverage on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set an “equal weight” rating and a $46.00 price target on the biotechnology company’s stock. Barclays PLC’s price target would indicate a potential upside of 6.95% from the stock’s previous close.

A number of other brokerages have also issued reports on SRPT. Janney Montgomery Scott upped their price target on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Robert W. Baird restated an “outperform” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday. Finally, Morgan Stanley restated an “equal weight” rating and set a $33.00 price target (up previously from $31.00) on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $62.31.

Sarepta Therapeutics (SRPT) traded down 5.22% during midday trading on Wednesday, reaching $43.01. 2,882,617 shares of the company’s stock were exchanged. Sarepta Therapeutics has a 12-month low of $25.47 and a 12-month high of $63.73. The stock’s market capitalization is $2.77 billion. The stock’s 50-day moving average is $39.34 and its 200-day moving average is $34.16.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same quarter in the previous year, the company posted ($1.19) EPS. The company’s revenue for the quarter was up 350000.0% compared to the same quarter last year. On average, equities analysts forecast that Sarepta Therapeutics will post ($1.23) earnings per share for the current year.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/10/sarepta-therapeutics-inc-srpt-now-covered-by-barclays-plc.html.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the transaction, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at $1,711,176. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the transaction, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,056 shares of company stock worth $3,224,208. Insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Asymmetry Capital Management L.P. lifted its holdings in Sarepta Therapeutics by 82.2% during the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock valued at $5,353,000 after purchasing an additional 71,630 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in Sarepta Therapeutics by 85.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock valued at $704,000 after purchasing an additional 9,635 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Sarepta Therapeutics by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 1,435 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in Sarepta Therapeutics during the second quarter valued at $3,806,000. 65.43% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.